Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Free Cash Flow (2023 - 2025)

Historic Free Cash Flow for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $301.0 million.

  • Genmab A's Free Cash Flow fell 2262.21% to $301.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 532.86%. This contributed to the annual value of -$6.0 billion for FY2025, which is 64858.96% down from last year.
  • Genmab A's Free Cash Flow amounted to $301.0 million in Q4 2025, which was down 2262.21% from $536.0 million recorded in Q3 2025.
  • Over the past 5 years, Genmab A's Free Cash Flow peaked at $536.0 million during Q3 2025, and registered a low of -$4.6 billion during Q4 2023.
  • Moreover, its 3-year median value for Free Cash Flow was $287.0 million (2025), whereas its average is -$258.3 million.
  • Per our database at Business Quant, Genmab A's Free Cash Flow surged by 10838.9% in 2024 and then plummeted by 7168.95% in 2025.
  • Genmab A's Free Cash Flow (Quarter) stood at -$4.6 billion in 2023, then soared by 108.39% to $389.0 million in 2024, then fell by 22.62% to $301.0 million in 2025.
  • Its last three reported values are $301.0 million in Q4 2025, $536.0 million for Q3 2025, and $62.0 million during Q2 2025.